Literature DB >> 3924146

[Aminoglutethimide-induced dyslipemia. Clinical study].

J Bonneterre, M Nguyen, B Hecquet, C Fournier, A Demaille.   

Abstract

Plasma levels of cholesterol, HDL cholesterol (HDL chol), LDL cholesterol (LDL chol), triglycerides, Al apoprotein and B apoprotein were studied in 73 patients receiving 500 mg aminoglutethimide (AG)/day and 40 mg hydrocortisone/day for advanced breast cancer. These dosages were done before treatment and then repeated during AG therapy. When all patients were considered together, a significant increase of cholesterol, HDL chol, LDL chol and Al apoprotein was noted. If one considers two groups of patients: group A (where cholesterol and triglycerides plasma levels were normal before treatment) and group B (where cholesterol and/or triglycerides plasma levels were high before treatment), it appears that variations differ in both groups. In group A patients we found an increase in cholesterol, chol LDL, B apoprotein and to a lesser extent Al apoprotein plasma levels. In group B patients there was an increase in cholesterol, HDL chol and Al apoprotein plasma levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924146

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

Review 1.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Variations in lipoproteins during aminoglutethimide therapy.

Authors:  J Bonneterre; N Ghalim; M Nguyen; P Puchois; A Demaille; C Demarquilly; J C Fruchart
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.